What are Wegovy pills?

A new presentation with its own instructions

The tablet licence covers eligible adults with obesity, or overweight and a weight-related condition, alongside diet and activity. [2] Approval does not by itself establish NHS funding, local availability or the right treatment for a particular person.

Check that any article you are reading explicitly concerns Wegovy tablets. A report about an injection, another oral semaglutide brand or a trial using a different dose cannot supply all the instructions for this product. The date matters too: an article written before June 2026 may describe an investigational medicine rather than the authorised UK presentation.

What the daily routine requires

The patient leaflet says to take the tablet on an empty stomach after a recommended fast of at least eight hours. Swallow it whole with water, up to 120 mL; do not split, crush or chew it. Wait at least 30 minutes before eating, drinking or taking other oral medicines. [3]

This is a useful routine to discuss before choosing treatment. Think through early starts, shift work, breakfast with children and medicines you already take on waking. Ask a pharmacist to help arrange medicines with conflicting timing requirements. Do not simply move another essential medicine or invent a shorter waiting period to make the routine easier.

For a missed tablet, the leaflet says to skip it and take the next dose the following day; do not double up. If you repeatedly miss treatment, tell the prescriber so the problem can be addressed. [3]

Why the strengths look different from injection doses

The labelled sequence starts at 1.5 mg daily, then 4 mg, 9 mg and 25 mg, with at least a month at each preceding level. [1] The prescriber decides the plan and how to handle tolerability.

The tablet and injection are absorbed differently. The oral product information contains specific switching guidance because an arithmetic conversion is not reliable. A 25 mg tablet should not be interpreted as “ten times stronger” than a 2.4 mg injection, and a weekly injection dose should not be divided by seven to choose a tablet. [2]

If a switch is proposed, ask for the last date on the old product, first date on the new product, exact strength and review arrangements in writing. Check the plan with the supplying pharmacy if anything differs from the dispensing label.

What OASIS 4 actually tested

OASIS 4 randomised 307 adults without diabetes to daily oral semaglutide 25 mg or placebo with lifestyle intervention. At week 64, average weight reduction was 13.6% versus 2.2% in the treatment-policy analysis. Digestive adverse events were reported in 74.0% versus 42.2%. The study was funded by Novo Nordisk. [4]

Some summaries instead quote 16.6%. That comes from an analysis estimating outcomes if participants continued the trial product without rescue treatment. It answers a different question from the 13.6% figure; neither is a promise for an individual. [2]

The study compared tablets with placebo, not with every injection now available. It therefore cannot establish that tablets are universally better, worse or equivalent to those products. A practical comparison needs the evidence, side-effect burden and treatment routine, rather than the largest headline number alone.

The oral route still requires safety checks

Taking semaglutide by mouth does not remove its important warnings. The tablet product information includes gastrointestinal problems, dehydration, pancreatitis and precautions involving other medicines. People using insulin or sulfonylureas need a clinician-led glucose-management plan. [2]

Sudden loss or rapid deterioration of vision needs urgent assessment; the MHRA's semaglutide safety update includes the very rare risk of NAION. [5]

Ask specifically about pregnancy plans and what to do before an operation. Give the prescriber a complete list of medicines and supplements, including anything obtained online. Tell the anaesthetic team about GLP-1 treatment before general anaesthesia or deep sedation. [6]

Questions for a real-world treatment decision

Ask whether the service can supply the exact formulation, how follow-up works and what support is included. The MHRA's June announcement said NHS use would need the usual assessment process. [1] That dated statement is not a live stock or funding checker.

Compare the total cost of the proposed course and reviews, rather than the cheapest introductory pack. If you are choosing a tablet because you dislike injections, ask whether the daily routine solves your main difficulty. If food timing is the difficulty, bring that up directly. A preference is useful clinical information, not something to hide until after prescribing.

Questions and answers